On 4 and 5 September in Münsbach, Luxembourg, Alzheimer Europe (AE) organised and jointly facilitated a consultation with the European Working Group of People with Dementia (EWGPWD) and ROADMAP project colleagues from the University of Edinburgh
On 15 September Alzheimer Europe, on behalf of Alzheimer’s Disease International (ADI) delivered a statement to 53 governments attending the 67th meeting of the World Health Organization (WHO) Committee for Europe meeting in Budapest, Hungary.
On 26 September, Axovant Sciences, a clinical-stage biopharmaceutical company developing novel therapeutic solutions to treat dementia, announced results of its MINDSET Phase 3 clinical trial for the treatment of mild to moderate Alzheimer’s disease (AD)
This newsletter received funding under an operating grant from the European Union’s Health Programme (2014-2020).
The content of this newsletter represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.